Form 8-K - Current report:
SEC Accession No. 0001641172-25-001822
Filing Date
2025-03-31
Accepted
2025-03-31 16:59:31
Documents
15
Period of Report
2025-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40816
2 ex99-1.htm EX-99.1 69913
3 ex99-1_001.jpg GRAPHIC 18312
  Complete submission text file 0001641172-25-001822.txt   320932

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cldi-20250331.xsd EX-101.SCH 3017
5 XBRL LABEL FILE cldi-20250331_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE cldi-20250331_pre.xml EX-101.PRE 22360
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3822
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 25794604
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)